MétaCan
Menu
Back to cohort

Influence of salmonella-IL2 in combination with FOLFIRINOX on overall and progression-free survival in stage IV metastatic pancreatic cancer.

2025· article· en· W4410805231 on OpenAlexaffabout
Daniel A. Saltzman, Petr Kavan, Lance B. Augustin, Janet L. Schottel, James T. Lee, Jordan Moradian, Eddie Moradian, Gerald Batist

Bibliographic record

VenueJournal of Clinical Oncology · 2025
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicCancer Research and Treatments
Canadian institutionsJewish General Hospital
Fundersnot available
KeywordsFOLFIRINOXMedicinePancreatic cancerOncologyStage (stratigraphy)Internal medicineProgression-free survivalOverall survivalCancerOxaliplatinColorectal cancer

Abstract

fetched live from OpenAlex

2571 Background: Salmonella-IL2 is an attenuated Salmonella Typhimurium strain carrying the human gene for IL-2. When orally administered, the bacterium colonizes tumors and locally releases IL-2, triggering immunologically-mediated tumor cell killing without untoward side effects. Salmonella-IL2 was tested in a phase 2 clinical trial in which patients with stage IV metastatic pancreatic cancer were treated with standard of care chemotherapy (SOC) combined with Salmonella-IL2. Methods: A Health Canada and local IRB approved, non-randomized, two-arm human study evaluated the combination of Salmonella-IL2 with standard of care (SOC) chemotherapy; Arm One patients received Salmonella-IL2 plus FOLFIRINOX (FFX). Arm Two patients received Salmonella-IL2 plus Gemcitabine/nab-Paclitaxel (GEM/nabP). Overall survival (OS), progression-free survival (PFS), safety, and biomarker data in each arm were compared to corresponding values for reference patients (SOC Controls) receiving care at the study site in the four years preceding the clinical trial (2016 to 2020). Four patients with stage IV pancreatic cancer were treated via Salspera’s Expanded Access Program (EAP) using the Arm One regimen. Results: In total, 34 patients (30 in the trial, 4 via EAP) were enrolled: 26 received Salmonella-IL2 with FOLFIRINOX (average age 58.7 years, range 32-74, 54% born female) and eight received Salmonella-IL2 with GEM/NabP (average age 68 years, range 56-82, 54% born female). SOC Control patients comprised 37 administered FOLFIRINOX (average age 58 years; range 33-75 years; 46% born female) and 31 given GEM/nabP (average age 65.1 years; range 45-84 years; 42% born female). Patients receiving more than five doses of Salmonella-IL2 with FOLFIRINOX (n = 20) had a mPFS of 15 months vs. 5.8 months in control patients who had received only FOLFIRNOX (p < 0.0001, 95% CI, HR 0.3, Concordance Index 0.64). For those same compared cohorts, the mOS was 20.3 months vs. 11.5 months (p = 0.07, 95% CI. HR 0.59, Concordance Index 0.59). Only eight patients were enrolled in the GEM/NabP Arm thus limiting useful conclusions. Overall, 41 serious adverse events were noted and attributed to SOC chemotherapy agents but none to Salmonella-IL2. Conclusions: Addition of Salmonella-IL2 to FOLFIRINOX for treating stage IV pancreatic cancer is associated with increased mPFS and mOS. A multicenter, randomized, phase III trial is warranted. Clinical trial information: NCT04589234 .

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.025
Threshold uncertainty score0.248

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.048
GPT teacher head0.460
Teacher spread0.412 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicCancer Research and TreatmentsFrench-language works237,207